UGN-104
Phase 3RecruitingInterest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Urinary Tract Urothelial Carcinoma
Conditions
Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
Trial Timeline
Aug 6, 2025 → Oct 1, 2027
NCT ID
NCT06774131About UGN-104
UGN-104 is a phase 3 stage product being developed by UroGen Pharma for Upper Urinary Tract Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06774131. Target conditions include Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma.
What happened to similar drugs?
6 of 14 similar drugs in Upper Urinary Tract Urothelial Carcinoma were approved
Approved (6) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06774131 | Phase 3 | Recruiting |
Competing Products
20 competing products in Upper Urinary Tract Urothelial Carcinoma